Can Zoetis Stock Jump 30%

For questions about this article or underlying research, email [email protected].

Zoetis (ZTS) stock trades 45.1% below its 52-week high, reached on October 27, 2025. Zoetis's chances of a 30% jump depend on whether its cash holds up while fewer pets visit the vet. The stock has climbed that much within a single year in 8 of the last 10 calendar years. Zoetis produces free cash worth 6.8% of its market value, compared with 4.3% for the median S&P 500 company. A yield that high marks either a business on sale or one the market expects to shrink. So what does that cash mean for you as an owner?

Why Does Zoetis's Cash Yield Matter To An Owner?

As a shareholder, you own a slice of the free cash the business produces, regardless of whether it is paid out to you. Cash that stays in the company still belongs to the company's owners. When the broader market recognizes that cash, the stock price tends to follow, especially when that cash is growing.

Zoetis owes more than it holds, so part of its cash must service debt before it belongs to you. The company carries net debt equal to 22.4% of its market value. Measured against market value plus that net debt, the free cash yield is 5.6%.

How Zoetis Makes Its Cash

Zoetis sells medicines and vaccines for pets and livestock. Parasiticides, its largest product line, brought in $2.34 billion in fiscal 2025. The company earns wide margins on these treatments: its operating margin was 37.6% over the twelve months to June 2026, about three times the 12.8% median for its peers. The business also requires little spending to keep running, as capital spending took only 18.5% of its cash from operations.

This combination of wide margins and low capital needs has made the cash grow. Free cash flow totaled $1.29 billion over the twelve months to June 2023 and climbed to $2.10 billion over the twelve months to June 2024. It then rose to $2.27 billion in the year to June 2025, and to $2.32 billion in the year to June 2026.

Debt has grown as well. Total debt reached $9.24 billion at June 30, 2026, compared with $6.79 billion a year earlier. Even so, operating income covered interest expense 15.1 times over the latest twelve months.

What Has Gone Wrong In Zoetis's Pet Business?

Pet owners are visiting the vet less often and spending more carefully, while rivals offer steeper discounts. Management cut its fiscal 2026 revenue guide on August 6, 2026, dropping the midpoint to $9.22 billion from $9.82 billion. The company blamed continued clinic visit declines, more value-conscious pet owners and heavier promotions, mainly in Dermatology and U.S. parasiticides.

Dermatology shows the damage most clearly. Key Dermatology sales fell 16% to $395 million in the second quarter of fiscal 2026, and management expects its volume and share to stay under pressure now that a new competitor has entered the U.S. market. In response, management is offering more discounting at the clinic without cutting list prices, along with cost and productivity actions.

Total sales across the company have held up so far. Reported revenue for the twelve months to June 2026 still grew 1.5% from a year earlier. Yet the stock trades at 12.9 times earnings, against 22.9 for the S&P 500, so the price appears to assume the slide lasts.

What Should Zoetis Owners Watch Next?

Two questions remain open. The first is whether free cash flow will keep rising from its June 2026 level while management expects fiscal 2026 sales to fall 1% to 3%, excluding currency effects and divestitures. The second is whether Zoetis can keep carrying a debt load that has grown over the past year. Twelve-month free cash flow and total debt are the two numbers to watch when Zoetis reports its third quarter of fiscal 2026.

Does This Mean You Should Act On ZTS?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.

Spot an error or want more like this? Tell us in 10 seconds.